Compass Therapeutics Investor Presentation Deck

Phase 1a CTX-009 Monotherapy Data Clinical activity at RP2D dosages (10 and 12.5 mg/kg) All patients (n=16) Colorectal Cancer (n=6) Gastric Cancer (n=8) COMPASS THERAPEUTICS Prior VEGF Targeted Therapy 75% 100% 63% Partial Response (PR) 19% 33% 13% Stable Disease (SD) 50% 33% 63% Clinical Benefit Rate (PR + SD) 69% 67% 75% Median Time to Progression (TTP) (Months) 3.9 6.7 3.9 11

View entire presentation